Can chemotherapy be omitted for patients with N0 or N1 endocrine-sensitive breast cancer treated with gonadotropin-releasing hormone agonist and tamoxifen?
Juhyeon LeeChan Sub ParkJeong Hun OhIn-Chul ParkMin-Ki SeongWoo Chul NohHyun-Ah KimPublished in: Annals of surgical treatment and research (2023)
Patients derived no significant survival benefit from undergoing a chemotherapy regimen before receiving tamoxifen and GnRH agonist therapy compared to forgoing such chemotherapy.
Keyphrases
- locally advanced
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- breast cancer cells
- estrogen receptor
- prognostic factors
- positive breast cancer
- peritoneal dialysis
- stem cells
- squamous cell carcinoma
- radiation therapy
- mesenchymal stem cells
- rectal cancer
- patient reported outcomes
- cell therapy
- bone marrow